“Drug Repurposing of Loratadine As a DNMT1 Inhibitor: Comparative Evaluation With Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells”. Precision Medicine Communications, vol. 4, no. 2, Dec. 2024, pp. 125-37, https://doi.org/10.55627/pmc.004.02.1083.